Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 Combine With Pembrolizumab Injection in Patients With Locally Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 Combine With Pembrolizumab Injection in Patients With Locally Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efineptakin alfa (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Head and neck cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors I-MAB Biopharma; TJ Biopharma

    • Most Recent Events

    • 30 Jan 2024 Planned End Date changed from 1 Feb 2024 to 31 Dec 2024.
    • 30 Jan 2024 Planned primary completion date changed from 1 Sep 2023 to 30 Jun 2024.
    • 30 Jan 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top